Germany
Japan
United Kingdom
China
ALK mouse monoclonal antibody, clone OTI1A4
| Applications | IHC, LMNX, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
Antibodies
View as table Download
.jpg?d=110x100 "User supplied image")
Rabbit anti-VEGFR (Phospho-Tyr951) polyclonal antibody (Phospho-specific)
| Applications | IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against synthesized phosphopeptide derived from humanVEGFR2 around the phosphorylation site of tyrosine 951 (K-D-YP-V-G). |
| Modifications | Phospho-specific |
BLK Rabbit Polyclonal Antibody
| Applications | IF, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | This BLK antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human BLK. |
Rabbit polyclonal RIPK2 (Ser176) antibody(Phospho-specific)
| Applications | IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against synthesized phosphopeptide derived from human RIPK2 around the phosphorylation site of serine 176 (S-L-SP-Q-S). |
| Modifications | Phospho-specific |
Rabbit polyclonal TGFBR2 (Ab-250) antibody
| Applications | IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against synthesized non-phosphopeptide derived from human TGFBR2 around the phosphorylation site of serine 250 (D-R-SP-D-I). |
Rabbit polyclonal CaMKII (Thr305) antibody(Phospho-specific)
| Applications | IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against synthesized phosphopeptide derived from human CaMKII around the phosphorylation site of threonine 305 (I-L-TP-T-M). |
| Modifications | Phospho-specific |
Rabbit polyclonal CDK5 (Ab-15) antibody
| Applications | IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against synthesized non-phosphopeptide derived from human CDK5 around the phosphorylation site of tyrosine 15 (G-T-YP-G-T) |
Rabbit polyclonal MAP2K7 (Ser271) antibody(Phospho-specific)
| Applications | IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against synthesized phosphopeptide derived from human MAP2K7 around the phosphorylation site of serine 271 (V-D-SP-K-A). |
| Modifications | Phospho-specific |
Rabbit polyclonal ETK / BMX(Ab-566) antibody
| Applications | IF, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against synthesized non-phosphopeptide derived from human ETK around the phosphorylation site of tyrosine 566 (D-Q-YP-V-S). |
Rabbit Polyclonal Antibody against BRAF (Center)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | This B-RAF antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 424-453 amino acids from the Central region of human B-RAF. |
Rabbit polyclonal CSFR (Ab-809) antibody
| Applications | IF, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against synthesized non-phosphopeptide derived from human CSFR around the phosphorylation site of tyrosine 809 (S-N-YP-I-V). |
Rabbit polyclonal p38 MAPK (Ab-322) antibody
| Applications | IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against synthesized non-phosphopeptide derived from human p38 MAPK around the phosphorylation site of tyreonine 322 (D-P-Y-D-Q). |
Rabbit Polyclonal Antibody against AKT2 (N-term)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | This AKT2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 93-123 amino acids from the N-terminal region of human AKT2. |
Rabbit Polyclonal antibody to FAST (Fas-activated serine/threonine kinase)
| Applications | IF, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | Recombinant fragment corresponding to a region within amino acids 346 and 549 of FAST (Uniprot ID#Q14296) |
Rabbit polyclonal COT (Ab-290) antibody
| Applications | IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against synthesized non-phosphopeptide derived from human COT around the phosphorylation site of threonine 290 (R-G-TP-E-I). |
Rabbit polyclonal Ret (Ab-905) antibody
| Applications | IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against synthesized non-phosphopeptide derived from human Ret around the phosphorylation site of tyrosine 905 (D-S-YP-V-K). |
Rabbit polyclonal anti-MAP3K4 antibody
| Applications | IHC |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against synthesized peptide derived from C-terminal of human MAP3K4. |
Rabbit polyclonal RIPK2 (Ab-176) antibody
| Applications | IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against synthesized non-phosphopeptide derived from human RIPK2 around the phosphorylation site of serine 176 (S-L-SP-Q-S). |
Active filters
Category
- Antibodies
Reactivities
- Mouse
Applications
- IHC
Conjugates
- Unconjugated
Families
- Protein Kinase
Availabilities
- In Stock
Filter by
Target Symbol
- MAP2K1 (69)
- ERBB2 (44)
- MAP2K3 (37)
- AKT1 (19)
- MTOR (19)
- BTK (16)
- EGFR (15)
- TLK2 (15)
- BRAF (14)
- FGFR2 (11)
- MAPK9 (11)
- MAP2K4 (10)
- PRKCE (10)
- ROR2 (10)
- ALK (9)
- CHEK2 (9)
- ERBB3 (9)
- PIM2 (9)
- TYRO3 (9)
- LIMK1 (8)
- MAPK1 (8)
- MARK3 (8)
- PTK2 (8)
- RPS6KB1 (8)
- STK39 (8)
- TP53RK (8)
- MAPK13 (7)
- MET (7)
- NRBP1 (7)
- PAK1 (7)
- PLK1 (7)
- CSNK1G1 (6)
- MAP2K2 (6)
- NEK6 (6)
- NTRK1 (6)
- ACVR2A (5)
- CAMK2B (5)
- CDKL1 (5)
- FRK (5)
- MAP3K8 (5)
- MAPK4 (5)
- MAPK8 (5)
- NTRK2 (5)
- PDGFRA (5)
- PRKD2 (5)
- TRIM28 (5)
- AKT2 (4)
- AKT3 (4)
- ARAF (4)
- CDKL2 (4)
- CSNK1E (4)
- DAPK2 (4)
- FGFR3 (4)
- GSK3A (4)
- HIPK1 (4)
- PDGFRB (4)
- PHKG2 (4)
- PRKD3 (4)
- RAF1 (4)
- SRC (4)
- STK11 (4)
- STK38L (4)
- TGFBR2 (4)
- TRIB1 (4)
- TRIB2 (4)
- TRIM24 (4)
- TRPM7 (4)
- AATK (3)
- ACVR1C (3)
- BMX (3)
- CDK15 (3)
- CDK5 (3)
- CSNK1A1 (3)
- DCLK1 (3)
- EIF2AK3 (3)
- JAK2 (3)
- MAP3K4 (3)
- MAPK3 (3)
- MARK4 (3)
- NTRK3 (3)
- PAK2 (3)
- PAK5 (3)
- PIK3R4 (3)
- PRKCA (3)
- PRKD1 (3)
- RPS6KA1 (3)
- STK3 (3)
- TNK2 (3)
- TRIM33 (3)
- TWF1 (3)
- ADCK1 (2)
- BLK (2)
- BMPR2 (2)
- CAMK1D (2)
- CAMK2A (2)
- CDK1 (2)
- CHUK (2)
- COQ8B (2)
- CSF1R (2)
- CSNK1G2 (2)
Antibody Hosts
Clonalities
Knockout (KO) Validation
Modifications
Pathways
- MAPK signaling pathway (328)
- Pathways in cancer (309)
- ErbB signaling pathway (302)
- Focal adhesion (258)
- Prostate cancer (237)
- Fc epsilon RI signaling pathway (228)
- Pancreatic cancer (220)
- GnRH signaling pathway (209)
- Toll-like receptor signaling pathway (202)
- Neurotrophin signaling pathway (201)
- Non-small cell lung cancer (199)
- Endometrial cancer (196)
- Insulin signaling pathway (192)
- Glioma (191)
- Colorectal cancer (188)
- Regulation of actin cytoskeleton (185)
- Acute myeloid leukemia (177)
- Bladder cancer (177)
- Progesterone-mediated oocyte maturation (177)
- Melanoma (169)
- T cell receptor signaling pathway (169)
- Chemokine signaling pathway (165)
- Renal cell carcinoma (158)
- Fc gamma R-mediated phagocytosis (155)
- Chronic myeloid leukemia (150)
- VEGF signaling pathway (148)
- B cell receptor signaling pathway (137)
- Vascular smooth muscle contraction (136)
- Gap junction (134)
- Long-term potentiation (127)
- Natural killer cell mediated cytotoxicity (122)
- Long-term depression (117)
- Oocyte meiosis (110)
- Thyroid cancer (108)
- Melanogenesis (106)
- Calcium signaling pathway (101)
- Adherens junction (99)
- Dorso-ventral axis formation (95)
- Prion diseases (91)
- mTOR signaling pathway (91)
- Endocytosis (83)
- Adipocytokine signaling pathway (76)
- Epithelial cell signaling in Helicobacter pylori infection (75)
- Axon guidance (67)
- Type II diabetes mellitus (59)
- Cytokine-cytokine receptor interaction (52)
- Amyotrophic lateral sclerosis (ALS) (50)
- Tight junction (50)
- Wnt signaling pathway (48)
- NOD-like receptor signaling pathway (45)
- Apoptosis (43)
- TGF-beta signaling pathway (42)
- Small cell lung cancer (38)
- RIG-I-like receptor signaling pathway (34)
- Jak-STAT signaling pathway (33)
- Leukocyte transendothelial migration (28)
- Cell cycle (24)
- Hedgehog signaling pathway (21)
- Alzheimer's disease (17)
- Primary immunodeficiency (16)
- Olfactory transduction (15)
- p53 signaling pathway (12)
- Pathogenic Escherichia coli infection (8)
- Vibrio cholerae infection (8)
- Regulation of autophagy (6)
- Circadian rhythm - mammal (4)
- Dilated cardiomyopathy (4)
- Hematopoietic cell lineage (4)
- Phosphatidylinositol signaling system (4)
- Taste transduction (4)
- Cytosolic DNA-sensing pathway (3)
- Hypertrophic cardiomyopathy (HCM) (3)
- Viral myocarditis (3)
- PPAR signaling pathway (2)
- Basal cell carcinoma (1)
- Basal transcription factors (1)
- Non-homologous end-joining (1)
- Purine metabolism (1)
- Ubiquitin mediated proteolysis (1)